Oncorus, Inc. logo

Oncorus, Inc.

Oncorus is an early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus, is an immuno-oncology company developing next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://oncorus.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
50 Hampshire St.Suite 401, MA, 02139
Cambridge
United States
Email
Contact Number
+1 857-320-6400

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/oncorus-inc.” connections=”true” suffix=””]

Oncorus uses a next-generation oncolytic herpes simplex virus (oHSV) immunotherapy platform to improve upon first generation oncolytic viruses.

In Dec 2016, Oncorus raised $61 Mn in a series A round led by MPM Capital and Deerfield Management, Arkin Bio Ventures, Celgene, Inc., Excelyrate Capital, Long March Investment Fund, MPMs SunStates Fund and Astellas Venture Management LLC.